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Objective: To conﬁrm the superiority of transdermal rotigotine up to 16 mg/24 h over placebo, and non-
inferiority to ropinirole, in Japanese Parkinson's disease (PD) patients on concomitant levodopa therapy.
Methods: This trial was a randomized, double-blind, double-dummy, three-arm parallel group placebo-
and ropinirole-controlled trial. Four-hundred and twenty PD patients whose motor symptoms were not
well controlled by levodopa treatment were randomized 2:2:1 to receive rotigotine, ropinirole (up to
15 mg/day) or placebo during a 16-week treatment period followed by a 4-week taper period. The
primary variable was change in the Uniﬁed Parkinson's Disease Rating Scale (UPDRS) Part III (ON state)
sum score from baseline to the end of the treatment period.
Results: The difference in the change in the UPDRS Part III (ON state) sum score from baseline to the end
of treatment between rotigotine and placebo groups was 6.4 ± 1.2 (95% CI: 8.7 to 4.1; p < 0.001),
indicating superiority of rotigotine over placebo. The difference between rotigotine and ropinirole groups
was 1.4 ± 1.0 (95% CI: 3.2 to 0.5), below the non-inferiority margin, indicating the non-inferiority of
rotigotine to ropinirole. Application site reaction was seen in 57.7% of the patients in the rotigotine group
and in 18.6% in the ropinirole group (P < 0.001). No other safety issue was noted.
Conclusions: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed similar efﬁcacy to
ropinirole except that the application site reaction was much higher in the rotigotine group.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Long-term treatment of Parkinson's disease (PD) with levodopa
are frequently complicated by motor ﬂuctuations [1e3]. Ahlskog
and Muenter reported 42.1% motor ﬂuctuations and 38.5% dyski-
nesia in 4e6 years of treatment with levodopa; these ﬁgures rose
up to 69.6% and 87.8%, respectively, with more than 9 years of
treatment [2]. The use of dopamine agonists is associated with
lower frequencies of wearing off and dyskinesia compared toJuntendo University School of
Japan. Tel.: þ81 3 3813 3111.
no).
Ltd. This is an open access article ulevodopa in early stage PD [3,4]. Rotigotine is a non-ergot dopamine
agonist, which has been developed as a patch with high selectivity
for D2 and D3 receptors [5]. Rotigotine is superior to placebo in
patients with early-stage [6e9] and advanced PD patients [10e12].
In addition, rotigotine was non-inferior to ropinirole [8] and pra-
mipexole [10]. A clinical trial conducted in Japan showed superi-
ority of rotigotine over placebo in patients with PD on concomitant
levodopa therapy in the dose range of 2e16 mg/24 h [12]. We
conducted a randomized, double-blind trial to see the efﬁcacy and
safety of transdermal rotigotine in Japanese advanced PD patients.
We selected ropinirole as an active comparator drug, as it has been
proved to be efﬁcacious both in early stage [13e15] and advanced
stage PD patients [16,17]. As the maximum daily dose for rotigotine
has been set at 15 mg/24 h in Japan; we used this dose.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Design
The study is a randomized, double-blind, double-dummy, three-arm parallel
group, placebo- and ropinirole-controlled trial of rotigotine in Japanese PD patients
on levodopa. The study was conducted in compliance with ethical principles in
accordancewith the Declaration of Helsinki, the Pharmaceutical Affairs Law, and the
“Ordinance on Good Clinical Practice.” The protocol was approved by the institu-
tional review boards of each center, and written informed consent was obtained
from all patients participating in the trial. The study has been registered with
Clinicaltrials.gov (identiﬁer: NCT01628926) and in the Japan Primary Registries
Network (identiﬁer: Japic CTI-090888). The study was ﬁnancially supported by
Otsuka Pharmaceutical Company.
2.2. Patients
Sixty-two sites in Japan participated in the trial, with the patient enrollment
commencing in June 2009. We enrolled patients aged 30e79 years and with a
diagnosis of PD, Hoehn & Yahr stage of 2e4, and Uniﬁed Parkinson's Disease Rating
Scale (UPDRS) Part III sum score of 10 at screening (ON state), who were experi-
encing motor ﬂuctuations or whom levodopa could not be increased to an optimal
level because of side effects or other reasons. The levodopa doses were not changed
from the period 28 days before starting treatment. Diagnosis of PD was made ac-
cording to the UK Brain Bank criteria [18].
We excluded patients with psychiatric symptoms; orthostatic hypotension; a
history of epilepsy or convulsion; a history of serious cardiac disease, arrhythmia, or
QT prolongation; abnormal liver function; or a history of allergy to topical agents;
and female patients who were pregnant or lactating from the trial. Concomitant use
of drugs that may affect the symptoms of PD, cause QT prolongation, or interact with
ropinirole was prohibited. Levodopa, selegiline and entacapone could be used
concomitantly, provided there was no change in the dose from 28 days before the
ﬁrst dose of the study drug until the end of the treatment period. Anticholinergic
drugs, amantadine, droxidopa, and zonisamide could be used concomitantly, pro-
vided there was no change in the doses for 14 days before the ﬁrst dose of the study
drug or during the treatment period.
2.3. Randomization and treatment
Eligible patients were randomized 2:2:1 to receive rotigotine, ropinirole, or
placebo using a dynamic allocation procedure designed to balance the UPDRS Part III
(ON state) sum score, the presence/absence of OFF time, the presence/absence of
dystonia in the early morning, and responsiveness to prior dopamine receptor ag-
onists. A double-dummy technique was used to maintain blinding with placebo
patches or tablets.
We evaluated the enrolled patients every week until the maintenance dose is
determined and every two weeks thereafter. The treatment period consisted of a
maximum of 12 weeks of titration and at least 4 weeks of maintenance, and a dose
taper period of up to 4 weeks. Rotigotine or placebo patches were applied once daily
and ropinirole or placebo tablets were administered three times daily. Rotigotine
was delivered at an initial dose of 2 mg/24 h, and the dose was increased to 16 mg/
24 h in weekly increments of 2 mg/24 h. Ropinirole was administered at an initial
dose of 0.75 mg/day. The dose was increased to 3.0 mg/day in weekly increments of
0.75 mg/day and then was increased to 15 mg/day in weekly increments of 1.5 mg/
day. One level of back titration was allowed for rotigotine and ropinirole during the
titration period. Dose increments for either drug could be stopped if the optimal
dose or the maximally tolerated dose was reached, if adverse events resolved after
back titration, or if the maximum dose level was attained. The maintenance dose of
rotigotine and ropinirole was determined for each patient considering their efﬁcacy
and safety.
2.4. Efﬁcacy measurement
The primary variable was the change in the UPDRS Part III (ON state) sum score
from baseline toweek 16 of the treatment period (end of treatment, EOT). Secondary
variables included changes from baseline to EOT for the time spent in OFF, ON, and
ON with troublesome dyskinesia and changes from baseline to EOT for the score in
UPDRS Part II (ON), UPDRS Part II (OFF), UPDRS Part II (average ON and OFF state),
sum of UPDRS Part II (average ON and OFF state) þ UPDRS Part III scores, and PD
sleep scale-2 (PDSS-2) [19]. Additional secondary variables were the responder rate
sum score (patients with a 20% or 30% reduction in the UPDRS Part III sum score)
(ON state), and the responder rate in terms of the UPDRS Part II (average ON and OFF
state) sum score. Patient diaries were utilized, inwhich each patient described his or
her condition as off time, on time, on time with troublesome dyskinesia or sleep in
every 30min every day starting seven days prior to the initial drug administration to
EOT. Examination of the patients was done at the ON state.
2.5. Safety
Safety was assessed in all randomized patients who received at least one dose of
the test drugs. Safety variables were the frequency of the onset of adverse events,
laboratory values, blood pressure/pulse rate, electrocardiogram parameters, skinirritation assessment score, physical and neurologic examination, and frequencies of
compulsive disorder and impulse control disorder as assessed by the translated Jay
Modiﬁed Minnesota Impulsive Disorder Interview [20]. Regurgitation of the cardiac
valve and drug dependency were assessed separately by the specialist committees.
2.6. Sample size calculations
Based on the results of the late phase 2 trial of rotigotine in Japanese advanced
PD patients on levodopa [12] and the Japanese clinical trial of ropinirole [17], we
assumed effect sizes of 5.4 for the rotigotine and 5.0 for the ropinirole group and a
standard deviation (SD) of 9.0 for each group. The sample size required to show
superiority of rotigotine over placebo was calculated to be 88 and 44 patients for the
rotigotine and placebo groups, respectively, with a two-tailed signiﬁcance level of 5%
and 90% power. The margin for non-inferiority of rotigotine to ropinirole was set to
2.5 based on the range of effect size in clinical trials of rotigotine and other non-ergot
dopamine agonists [4,21,22]. The number of patients required to achieve 80% power
and an upper limit of the 95% conﬁdence interval (CI) for the difference between
rotigotine and ropinirole being lower than the non-inferiority margin was 152 per
group. Therefore, the target sample size was set as 160 patients each for the roti-
gotine and ropinirole groups and 80 patients for the placebo group.
2.7. Statistical analyses
The primary analysis of the primary variable was conducted using analysis of
covariance (ANCOVA) with treatment group as a ﬁxed factor. The different null
hypotheses were tested in a pre-assigned order (closed testing principle). The test
procedure startedwith a two-sided test between rotigotine and placebowith a¼ 5%.
If the P-value was signiﬁcant (i.e., rotigotine was superior to placebo), a non-
inferiority test was conducted to compare rotigotine with ropinirole. Non-
inferiority was accepted if the 95% CI for the difference between rotigotine and
ropinirole was within the pre-deﬁned non-inferiority margin of 2.5. For secondary
analyses of the primary variable, ANCOVA was applied with treatment group as a
ﬁxed factor and the corresponding baseline value as a covariate. Changes from
baseline to EOT in the secondary variables were assessed using ANCOVA. Responder
rates were compared between each group using c2 tests. Safety variables were
summarized using descriptive statistics and between-group comparisons were done
using c2 tests.
3. Results
We obtained responses from 546 patients. However, 126 pa-
tients were not randomized; 36 from consent withdrawal, 59 not
meeting the enrollment criteria, 31 from other reasons. Thus 420
patients were randomized (rotigotine 168, ropinirole 167, placebo
85). The full analysis set (FAS) included 414 patients because of
three not meeting the enrollment criteria and three not having any
valid post-baseline assessment of UPDRS Part III (ON state) sum
score, and the safety set 420 patients including all randomized
patients who received at least one dose of the test drugs (Fig.1). The
baseline characteristics of the 414 patients are shown in Table 1.
There were no differences between groups, except for PDSS-2,
which was higher in the placebo group than in the rotigotine and
ropinirole groups (p ¼ 0.023), and the patients receiving previous
treatment with entacaponewas higher in the ropinirole group than
in the placebo and rotigotine groups (p ¼ 0.03).
3.1. Treatment
After the start of the study, 26 patients in the rotigotine group,
23 in the ropinirole group and 17 in the placebo group discontinued
the study. The most common reason for discontinuation was
adverse events (AE) (13, 13, and 8 patients in the rotigotine, ropi-
nirole, and placebo groups, respectively). None of these patients
were seriously ill after the discontinuation of the test drugs.
Of the 420 patients in the safety analysis set, 381 (153, 153, and
75 patients in the rotigotine, ropinirole, and placebo groups,
respectively) entered the dose maintenance period. Of these pa-
tients, 24.8% (38 patients), 28.8% (44 patients), and 41.3% (31
patients) in the rotigotine, ropinirole, and placebo groups, respec-
tively, received dose increases up to the maximum maintenance
dose. The mean maintenance doses were 12.9 mg/24 h and 9.2 mg/
day in the rotigotine and ropinirole groups, respectively.
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The change in the UPDRS Part III (ON state) sum score from
baseline to EOT in the FAS was 10.9 ± 8.1, 9.5 ± 8.7,
and 4.5 ± 9.7 (mean ± SD) in the rotigotine, ropinirole, and pla-
cebo groups, respectively. The difference between the rotigotine
and the placebo group was 6.4 (95% CI: 8.7 to 4.1; p < 0.001),
and that between the ropinirole and the placebo group was 5.1
(95% CI: 7.4 to 2.8; p < 0.001), showing superiority of rotigotine
and ropinirole over placebo. The difference between the rotigotine
and the ropinirole group was 1.4 (95% CI: 3.2 to 0.5, p ¼ 0.156)
showing the non-inferiority of rotigotine to ropinirole.
Regarding motor ﬂuctuations (110/164 ¼ 67.1% in the rotigo-
tine,113/166 ¼ 68.1% in the ropinirole, and 57/84 ¼ 67.9% in the
placebo group, no statistical difference), off period decrease was
1.4 h in the rotigotine, 1.9 h in the ropinirole, and 0.4 h in the pla-
cebo group. The differences between the rotigotine and the placebo
and the ropinirole and the placebo group were signiﬁcant
(p ¼ 0.009 and p < 0.001, respectively). The difference between the
rotigotine and the ropinirole group was not signiﬁcant (P ¼ 0.148).
The comparisons between groups for other efﬁcacy variables are
shown in Table 2. The difference in the UPDRS Part II (average ON
and OFF state) sum score between the rotigotine and the placebo
group was 2.4 (95% CI: 3.3 to 1.5; p < 0.001) and that between
the ropinirole and the placebo group was 1.8 (95% CI: 2.7
to0.8; p < 0.001), while the difference between the rotigotine and
the ropinirole group was 0.6 (95% CI: 1.4 to 0.1; p ¼ 0.106). The
difference in the UPDRS Part II (OFF state) sum score between the
rotigotine and the placebo group was 2.4 (95% CI: 3.9 to 0.9;
p ¼ 0.002) and that between the ropinirole and the placebo group
was 1.4 (95% CI: 2.9 to 0.0; p ¼ 0.058), while the difference
between the rotigotine and the ropinirole group was 1.0 (95%
CI: 2.2 to 0.2; p ¼ 0.114).
Signiﬁcantly more patients in the rotigotine group were classi-
ﬁed as responders for UPDRS Part III (ON state), UPDRS Part II
(average ON and OFF state), and the sum of UPDRS Part II (average
ON and OFF state) þ UPDRS Part III compared with the placebo
group (Table 2). The ropinirole group also showed similar results
compared with the placebo group. More patients in the rotigotine
group were classiﬁed for 20% responder rate on UPDRS Part III (ON
state), 30% responder rate on UPDRS Part II (average ON and OFF
state), and 20% responder rate on the sum of UPDRS Part II (averageFig. 1. Disposition of patients. The numbers indicate the numON and OFF state) þ UPDRS Part III compared to the ropinirole
group.3.3. Safety outcomes
Adverse events occurred in 88.7% (149/168 patients), 77.8%
(130/167 patients), and 69.4% (59/85 patients) in the rotigotine,
ropinirole, and placebo groups, respectively. Adverse events with
an incidence of 3% are shown in Table 3. Most adverse events
were mild to moderate in severity, and the proportion of patients
with severe adverse events was similar in all three groups (8% in
both rotigotine and placebo groups, and 7% in the ropinirole group).
Only application site reaction was higher in the rotigotine than in
the ropinirole and the placebo group (57.7%, 18.6% and 15.3%,
respectively). All application site reactions were mild or moderate
in intensity. Skin irritation was evaluated using a six-grade skin
irritation assessment (, ±, þ, þþ, þþþ, þþþþ). Only 2.4% of
patients in the rotigotine group and none in the ropinirole and
placebo groups had a score of þþþ (concurrent erythema, edema
and papule; serous papule; and vesicle) during the dose titration
period. The proportion of patients in the rotigotine group with a
score of þþþ during the dose maintenance period was 0.7%. No
patients had skin irritation with a score of þþþþ (large blisters).
Three subjects in the rotigotine group discontinued the trial from
skin irritation.
Dyskinesias occurred in 16.1% (27/168), 13.8% (23/167), and 1.2%
(1/85) of patients in the rotigotine, ropinirole and placebo groups,
respectively. The difference between the rotigotine and the ropi-
nirole group was not signiﬁcant. Adverse events leading to treat-
ment discontinuation occurred in 7.7% (13/168), 7.8% (13/167), and
9.4% (8/85) of patients in the rotigotine, ropinirole, and placebo
groups, respectively. Sudden onset of sleep was observed in one
patient each in the rotigotine and ropinirole groups. Neither case
required treatment discontinuation or dose reduction.
Serious adverse events, which required hospitalization, occurred
in seven patients in the rotigotine, ﬁve in the ropinirole, and six in
the placebo group. Among them, serious adverse events related to
the test drugs include gastric ulcer, torticollis, and spinal compres-
sion fracture and posture abnormality in three patients in the roti-
gotine group, worsening of PD in one in the ropinirole group, and
angina pectoris and worsening of PD in the placebo group.ber of patients in each category in FAS (full analysis set).
Table 1
Baseline patient characteristics (full analysis set, n ¼ 414).
Rotigotine (n ¼ 164) Ropinirole (n ¼ 166) Placebo (n ¼ 84) p-Value
Gender
Male 61 (37.2%) 68 (41.0%) 42 (50.0%) 0.152a
Female 103 (62.8%) 98 (59.0%) 42 (50.0%)
Age (years) 64.8 (8.8) 67.0 (7.9) 65.3 (7.9) 0.066b
Duration of PD (years) 7.0 (4.9) 6.8 (4.2) 7.0 (4.2) 0.880b
Wearing off 107 (65.2%) 110 (66.3%) 57 (67.9%) 0.918a
Dyskinesias 42 (25.6%) 43 (25.9%) 15 (17.9%) 0.319a
Levodopa dose (mg) 367.7 (151.9) 350.6 (125.3) 370.5 (146.6) 0.764b
Previous concomitant anti-Parkinson’s medication
Entacapone 40 (24.4%) 57 (34.3%) 33 (39.3%) 0.033a
Anticholinergic drugs 33 (20.1%) 32 (19.3%) 16 (19.0%) 0.973a
Amantadine 39 (23.8%) 40 (24.1%) 27 (32.1%) 0.306a
Selegiline 60 (36.6%) 69 (41.6%) 35 (41.7%) 0.594a
Droxidopa 12 (7.3%) 11 (6.6%) 8 (9.5%) 0.709a
Zonisamide 16 (9.8%) 13 (7.8%) 12 (14.3%) 0.271a
Hoehn & Yahr average 2.7 (0.6) 2.8 (0.6) 2.8 (0.6) 0.204b
UPDRS Part III (ON state) 25.8 (10.6) 25.8 (11.0) 25.6 (10.4) 0.970b
UPDRS Part II (average ON and OFF state) 11.0 (6.2) 10.6 (5.6) 11.1 (7.0) 0.978b
UPDRS Part II (ON state) 8.5 (5.9) 7.8 (5.7) 7.9 (6.7) 0.357b
UPDRS Part II (OFF state) 14.9 (8.4; n ¼ 110) 15.3 (6.9; n ¼ 114) 15.8 (9.4; n ¼ 58) 0.562b
Sum of UPDRS Part II (average ON and OFF state) þ UPDRS Part III 36.9 (15.2) 36.4 (15.2) 36.7 (16.0) 0.909b
PDSS-2 12.3 (8.9) 14.3 (9.2) 15.0 (9.2) 0.023b
OFF time (hr) 4.5 (3.4; n ¼ 111) 5.0 (3.6; n ¼ 113) 4.9 (3.0; n ¼ 57) 0.359b
ON time (hr) 13.1 (3.6) 12.5 (3.8) 12.6 (3.7) 0.375b
ON time with troublesome dyskinesias (hr) 2.4 (2.6; n ¼ 23) 1.6 (1.5; n ¼ 16) 0.7 (1.2; n ¼ 5) 0.079b
Data are means (SD) or number (%).
UPDRS: uniﬁed Parkinson's disease rating scale; PDSS: Parkinson's disease sleep scale.
In this clinical trial, we deﬁned FAS as follows; Those whowere given the trial drugs at least once and at least one evaluation for the efﬁcacywasmade. However, those patients
who violated GCP, those who do not fulﬁll the enrollment criteria, and those who meet the exclusion criteria are not included in the FAS. According to this criteria, three
patients met the exclusion criteria, and in three patients there was no efﬁcacy evaluation after enrollment to the study.
a c2 test.
b KruskaleWallis test.
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in the ropinirole group, but none in the rotigotine and placebo
groups. The committee's assessment of results was of no clinically
signiﬁcant worsening of cardiac valve regurgitation in anyTable 2
Efﬁcacy variables at end of treatment (full analysis set, last observation carried forward)









UPDRS Part III (ON state) 10.9 9.5 4
UPDRS Part II (average ON and OFF state) 3.6 3.0 1
UPDRS Part II (ON state) 2.8 2.3 0
UPDRS Part II (OFF state) 4.9; n ¼ 109 3.9; n ¼ 111 2
Sum of UPDRS Part II
(average ON and OFF state) þ UPDRS Part III
14.6 12.5 5
PDSS-2 3.7 3.0 1
OFF time (hr) 1.4; n ¼ 110 1.9; n ¼ 113 0
ON time (hr) 1.4 1.6 0.2
ON time with troublesome dyskinesias (hr) 0.3; n ¼ 22 0.2; n ¼ 16 1
Responder analysis
UPDRS Part III (ON state)
20% responder 80.5 69.1 56
30% responder 69.5 60.6 39
UPDRS Part II (average ON and OFF state)
20% responder 65.2 56.7 47
30% responder 55.9 43.3 28
Sum of UPDRS Part II
(average ON and OFF state) þ UPDRS Part III
20% responder 78.3 66.5 51
30% responder 68.3 57.9 37
Change from baseline to EOT was assessed using analysis of covariance with baseline va
Adjusted LS means were calculated. Inter-group comparisons for responder rate were p
UPDRS: Uniﬁed Parkinson's Disease Rating Scale; PDSS: Parkinson's disease sleep scale.patients. Non-signiﬁcant difference was found regarding drug
dependency. Impulse control disorder rates were non-signiﬁcantly








Difference p-Value (95% CI) Difference p-Value (95% CI)
.5 6.4 <0.001 (8.6, 4.2) 1.4 0.137 (3.2, 0.4)
.2 2.4 <0.001 (3.3, 1.5) 0.6 0.106 (1.4, 0.1)
.6 2.2 <0.001 (3.1, 1.3) 0.5 0.201 (1.2, 0.3)
.4; n ¼ 57 2.4 0.002 (3.9, 0.9) 1.0 0.114 (2.2, 0.2)
.7 8.8 <0.001 (11.7, 6.0) 2.0 0.091 (4.4, 0.3)
.1 2.6 <0.001 (4.1, 1.1) 0.7 0.277 (1.9, 0.6)
.4; n ¼ 57 1.1 0.009 (1.9, 0.3) 0.5 0.148 (0.2, 1.2)
1.2 <0.001 (0.6, 1.8) 0.2 0.426 (0.7, 0.3)
.2; n ¼ 5 1.5 0.166 (0.7, 3.7) 0.1 0.860 (1.3, 1.5)
.6 23.9 <0.001 (11.6, 36.1) 11.4 0.017 (2.1, 20.7)
.8 29.8 <0.001 (17.1, 42.4) 8.9 0.090 (1.4, 19.2)
.0 18.2 0.006 (5.2, 31.2) 8.5 0.116 (2.1, 19.1)
.9 27.0 <0.001 (14.6, 39.4) 12.6 0.023 (1.8, 23.4)
.8 26.5 <0.001 (14.0, 38.9) 11.8 0.017 (2.2, 21.4)
.3 31.0 <0.001 (18.3, 43.6) 10.4 0.052 (0.0, 20.8)
lue as covariate.
erformed using the c2 test.
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We showed superiority of rotigotine and ropinirole to placebo
and non-inferiority of rotigotine to ropinirole up to 15 mg/day for
the primary efﬁcacy variable (UPDRS Part III sum score) in this
study. In addition, we showed reduction in off time in patients with
motor ﬂuctuations treatedwith rotigotine and ropinirole compared
with placebo. There was no difference between rotigotine and
ropinirole treatment.
As the maximum dose of ropinirole (15 mg/day) is lower in this
study compared to those reported in the western literature
(24 mg/day) [3,13e17], whether or not this difference might have
resulted in non-inferiority of rotigotine to ropinirole should be
discussed. First of all, 15 mg/day of ropinirole is the maximum
approved dose in Japan. Although themaximum administered dose
of ropinirole in this study was lower than those in the western
literature, the magnitude of improvement as measured by UPDRS
Part III sum score are similar between western and Japanese pa-
tients [13e17]. This may in part be due to the difference in the body
weight. As none of the previous studies have addressed the ques-
tion as to the doseeresponse relationship on ropinirole, we
compared the average dose of ropinirole and efﬁcacy in the pre-
vious studies. In the present study, average daily maintenance dose
of ropinirole was 9.2 mg/day and the average motor UPDRS score
decreased from 25.8 to 16.3 (9.5 points difference) after 16 weeks
and off time decreased by 1.9 h (34% reduction) in the ropinirole
group. In the study by Korczyn et al. the ﬁnal dose of ropinirole was
12.0 mg at three years' treatment [14]. The motor UPDRS reduced
from 23 to 14 at 24 weeks after the randomization. In the study by
Rascol et al. the average daily dose of ropinirole was 16.5 mg and
the UPDRS motor score decreased from 23 points to 14 points at
24 weeks [3]. In the study by Lieberman et al. [16], there was no
description in the ﬁnal average dose of ropinirole. Therefore, the
magnitude of the motor UPDRS decrease is about the same in these
studies. We wanted to compare the improvement in wearing off
with different doses of ropinirole; however, this was difﬁcult
because the total number of patients who showed improvement in
wearing off was not described [16].
Rotigotine is a patch formulation, which provides stable and
continuous stimulation of dopamine receptors. Continuous dopa-
minergic drug delivery was thought to be an effective strategy for PD
patients. Rotigotinewaswell tolerated, and therewere no signiﬁcant
safety issues with doses up to 16 mg/24 h compared to ropinirole upTable 3
Treatment-emergent adverse events occurring with an incidence of 3% in at least one
Number of patients (%)
Rotigotine (n ¼ 168) Ropinirole (n ¼ 1
Any adverse event 149 (88.7) 130 (77.8)
Application site reactionsa 97 (57.7) 31 (18.6)
Nasopharyngitis 28 (16.7) 24 (14.4)
Dyskinesia 27 (16.1) 23 (13.8)
Nausea 25 (14.9) 23 (13.8)
Vomiting 11 (6.5) 11 (6.6)
Somnolence 11 (6.5) 9 (5.4)
Contusion 7 (4.2) 2 (1.2)
Orthostatic hypotension 5 (3.0) 7 (4.2)
Blood creatine kinase increased 5 (3.0) 6 (3.6)
Hallucinationb 3 (1.8) 6 (3.6)
Back pain 3 (1.8) 5 (3)
Cystitis 3 (1.8) 3 (1.8)
Upper respiratory tract inﬂammation 3 (1.8) 1 (0.6)
Peripheral edema 0 2 (1.2)
Comparisons were made using the c2 test.
The safety set (420 patients) includes all randomized patients who received at least one
a Corresponds to the MedDRA term “Application and instillation site reactions”.
b Corresponds to the MedDRA terms “Hallucination”, “Hallucination, visual”, “Hallucinto 15 mg/day except the high incidence of application site reactions
in the rotigotine group, which may limit the use of rotigotine. In
conclusion, once-daily administration of the rotigotine patch is a
favorable option for the treatment of PD patients on levodopa.Author contributions
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